Non‐alcoholic Fatty Liver Disease

Rotman, Yaron; Kapuria, Devika

doi:10.1002/9781119436812.ch52

Cited by 1 publication

(1 citation statement)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current "multiple-or continuous-hit model" suggests the existence of different and continuous insults, which might be generated in individuals with T2DM or metabolic syndrome due to altered inter-organ crosstalk between liver, adipose tissue, intestine, and skeletal muscle (Fig. 1) [21]. These multiple insults would cooperatively and synergistically drive the development and progression of NAFLD, particularly in genetically predisposed individuals [22].…”

Section: Mechanisms and Consequences Of Metabolic Alterationsmentioning

confidence: 99%

Metabolic liver disease in diabetes – From mechanisms to clinical trials

et al. 2020

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) comprises fatty liver (steatosis), non-alcoholic steatohepatitis (NASH) and fibrosis/cirrhosis and may lead to end-stage liver failure or hepatocellular carcinoma. NAFLD is tightly associated with the most frequent metabolic disorders, such as obesity, metabolic syndrome, and type 2 diabetes mellitus (T2DM). Both multisystem diseases share several common mechanisms. Alterations of tissue communications include excessive lipid and later cytokine release by dysfunctional adipose tissue, intestinal dysbiosis and ectopic fat deposition in skeletal muscle. On the hepatocellular level, this leads to insulin resistance due to abnormal lipid handling and mitochondrial function. Over time, cellular oxidative stress and activation of inflammatory pathways, again supported by multiorgan crosstalk, determine NAFLD progression. Recent studies show that particularly the severe insulin resistant diabetes (SIRD) subgroup (cluster) associates with NAFLD and its accelerated progression and increases the risk of diabetes-related cardiovascular and kidney diseases, underpinning the critical role of insulin resistance. Consequently, lifestyle modification and certain drug classes used to treat T2DM have demonstrated effectiveness for treating NAFLD, but also some novel therapeutic concepts may be beneficial for both NAFLD and T2DM. This review addresses the bidirectional relationship between mechanisms underlying T2DM and NAFLD, the relevance of novel biomarkers for improving the diagnostic modalities and the identification of subgroups at specific risk of disease progression. Also, the role of metabolism-related drugs in NAFLD is discussed in light of the recent clinical trials. Finally, this review highlights some challenges to be addressed by future studies on NAFLD in the context of T2DM.

show abstract

Section: Mechanisms and Consequences Of Metabolic Alterationsmentioning

confidence: 99%